Wall Street Zen Downgrades Theravance Biopharma (NASDAQ:TBPH) to Hold

Wall Street Zen lowered shares of Theravance Biopharma (NASDAQ:TBPH - Free Report) from a buy rating to a hold rating in a research note issued to investors on Saturday morning.

A number of other analysts also recently issued reports on TBPH. BTIG Research lifted their price target on shares of Theravance Biopharma from $24.00 to $25.00 and gave the company a "buy" rating in a report on Friday, June 27th. Jones Trading raised Theravance Biopharma to a "strong-buy" rating and set a $24.00 price objective on the stock in a research report on Tuesday, June 17th. Four analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $16.60.

Theravance Biopharma Stock Up 0.3%

Shares of NASDAQ:TBPH traded up $0.03 during mid-day trading on Friday, reaching $11.50. 78,054 shares of the stock were exchanged, compared to its average volume of 260,770. The company has a market cap of $575.15 million, a P/E ratio of -9.75 and a beta of -0.02. The stock's 50 day simple moving average is $10.33 and its 200-day simple moving average is $9.61. Theravance Biopharma has a one year low of $7.44 and a one year high of $11.82.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last announced its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.16). The business had revenue of $15.39 million for the quarter, compared to the consensus estimate of $28.08 million. Theravance Biopharma had a negative net margin of 89.38% and a negative return on equity of 32.37%. Analysts anticipate that Theravance Biopharma will post -1.09 EPS for the current fiscal year.

Insider Buying and Selling at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 24,000 shares of the business's stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $11.00, for a total transaction of $264,000.00. Following the completion of the transaction, the senior vice president directly owned 336,918 shares of the company's stock, valued at approximately $3,706,098. The trade was a 6.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 6.90% of the company's stock.

Hedge Funds Weigh In On Theravance Biopharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. raised its stake in shares of Theravance Biopharma by 0.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 293,936 shares of the biopharmaceutical company's stock worth $2,766,000 after purchasing an additional 2,060 shares during the last quarter. Teacher Retirement System of Texas purchased a new position in Theravance Biopharma during the fourth quarter worth $103,000. Magnetar Financial LLC raised its holdings in Theravance Biopharma by 125.8% in the 4th quarter. Magnetar Financial LLC now owns 27,511 shares of the biopharmaceutical company's stock valued at $259,000 after acquiring an additional 15,328 shares during the last quarter. American Century Companies Inc. increased its position in Theravance Biopharma by 11.9% during the fourth quarter. American Century Companies Inc. now owns 77,931 shares of the biopharmaceutical company's stock worth $733,000 after purchasing an additional 8,289 shares during the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new stake in shares of Theravance Biopharma in the fourth quarter worth $69,000. 99.10% of the stock is owned by institutional investors and hedge funds.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.